Management Team

Jean-Guillaume Lafay, C.E.O.

Jean-Guillaume Lafay
Chief Executive Officer (CEO)
Co-founder of Mablink Bioscience

Mr. Jean-Guillaume Lafay holds a master’s degree in “Medicinal Organic Chemistry” from the University of Lyon (France). He has a strong entrepreneurship background and a great experience in management. He joined a French-based biotechnology company in 2010 as Sales & Marketing Director.

Dr. Warren Viricel, PharmD, PhD
Chief Scientific Officer (CSO)
Co-founder of Mablink Bioscience

Dr. Warren Viricel holds a PharmD and a PhD in “Biomedical Engineering”, respectively from the University of Lyon (France) and the University of Montréal (Canada). Upon his return to France in 2016 he founded Lina Therapeutics and developed the proprietary “hydrophilic drug-linker ADC platform”, involving Pr. Joseph and Pr. Dumontet in the process. The technology was ultimately entirely transferred to Mablink in 2018. His expertise in medicinal organic chemistry, bioconjugation, pharmacology and antibody-drug conjugates makes him a key asset to the company.

Valerie Attuil-Audenis, C.O.O.

Dr. Valérie Attuil, PhD
Chief Operating Officer (COO)

Dr. Valérie Attuil holds a PhD in “Immunology” from the University of Lyon (France). She has worked 10 years in academia, specializing in virology and immunology. With her strong scientific background, she joined in 2010, a biotech company developing polyclonal and monoclonal antibodies, where she worked for 8 years as a product manager. She was liaising between R&D, production and marketing. She was also in charge of developing new projects and monitoring customer projects for the development of new antibodies.

Edouard Leroy, C.B.D.O.

Edouard Leroy
Chief Business Officer (CBO)

Mr. Edouard Leroy holds a master’s degree in “Physiology and Physiopathology” from the Sorbonne University of Paris (France). He began his career at Servier in a business intelligence team. He then joined a biotech company in the field of antibodies development. He continued his career as a sales manager for a global provider in Life Sciences solutions. Overall, Edouard has developed a professional network covering in particular the main players in the pharmaceutical and biotechnology industries in Europe and North America.

David Doreau

David Doreau
Chief Quality Officer (CQO)

Mr David Doreau holds an engineering degree in “Biotechnology” from the University of Technology of Compiègne (France). In 2012 he joined a French biotech company developing research-grade antibodies.
Before he joined Mablink Bioscience in 2021, he spent 3 years at Sanofi Pasteur’s production site of Marcy l’Etoile in the Quality Excellence division as LIMS functional administrator.

Scientific Advisory Board

Pr. Charles DUMONTET, MD, PhD
Scientific Advisory Board member
Co-founder of Mablink Bioscience

Pr. Charles Dumontet is Professor of Hematology at the University of Lyon, Deputy Director of the Centre de Recherche en Cancérologie de Lyon (CRCL), Director of the Antibodies Anticancer lab (UMR CNRS INSERM 1052) and Medical Doctor in Hematology at the Lyon South Hospital. He is the author of more than 300 peer-reviewed scientific publications and several patents.

Pr. Dumontet is a world reference in the therapeutic antibody and antibody-drug conjugate (ADC) fields of research. He has a critical and constructive outlook on clinical applications and development of ADCs and is involved in numerous international events in the field. He recently co-authored a review article on ADCs (« Strategies and challenges for the next generation of antibody-drug conjugates », Nat. Rev. Drug. Deliv. Review, 16(5), 315-337, 2017). Pr. Dumontet’s lab regularly collaborates with major European players in the immuno-oncology field (Roche, Sanofi, Servier, Pierre Fabre…).

Pr. Benoît Joseph, PhD
Scientific Advisory Board member
Co-founder of Mablink Bioscience

Pr. Benoît Joseph is Professor of Organic Chemistry and director of the SMITh lab at the Chemistry and Biochemistry Institute (ICBMS – UMR CNRS 5246) of the University of Lyon.

With more than 25 years of experience in chemical synthesis of cytotoxic compounds and more broadly in medicinal chemistry, Pr. Benoît Joseph is a key contributor regarding drug-linker chemical synthesis and the identification of new cytotoxic entities. He is the author of more than 90 peer-reviewed scientific publications and several patents.

Dr. Warren Viricel, PharmD, PhD
Scientific Advisory Board member
Co-founder of Mablink Bioscience

Dr. Warren Viricel holds a PharmD and a PhD in “Biomedical Engineering”, respectively from the University of Lyon (France) and the University of Montréal (Canada). Upon his return to France in 2016 he founded Lina Therapeutics and developed the proprietary “hydrophilic drug-linker ADC platform”, involving Pr. Joseph and Pr. Dumontet in the process. The technology was ultimately entirely transferred to Mablink in 2018. His expertise in medicinal organic chemistry, bioconjugation, pharmacology and antibody-drug conjugates makes him a key asset to the company.

Isabelle Ray-Cocquard

Pr. Isabelle Ray-Coquard, MD, PhD
Scientific Advisory Board member

Pr Isabelle Ray-Coquard is Professor of Medical Oncology at the University of Lyon, as well as a Medical oncologist at the Centre Léon Bérard. She also has a strong translational and clinical research activity, especially pertaining to gynecological cancers. She is and has been leading several national research networks (GINECO, ENGOT, GCIG). Pr Ray-Coquard is also at the interface with the industry for clinical studies, committees, and other meetings (Roche, AstraZeneca, PharmaMar, Genmab, Pfizer, Tesaro/GSK, Clovis, Mersana, Seagen, BMS, MSD…).

Pr Ray-Coquard is the current international principal investigator of 10 clinical studies, the PI of 23 multicenter studies and participated, or is participating, as investigator in more than 120 other therapeutic trials. She is also a member of several independent data monitoring committee regarding therapeutic trials in oncology since 2005.

Peter De Waele

Dr. Peter De Waele, PhD
Scientific Advisory Board member

Dr. Peter De Waele is the founder of Advanced Therapies Consulting and is a consultant to the industry and European Commission since 2006. Peter held different management positions, including Vice-President R&D and IP at Celyad, Chief Technology at CellTran. As COO of XCELLentis (which he founded) and Chief Therapeutics of Innogenetics, he was responsible for several multicenter international phase I and II clinical trials with monoclonal antibodies and other advanced biotechnology products.

Peter holds a master’s degree in “Biochemistry and Physiology” and a PhD in “Molecular Biology” from Ghent University (Belgium), where he worked on the generation of tumor-antigen specific recombinant antibody-toxin conjugates.

Stephane Moutel

Dr. Stephane Moutel, PhD
Scientific Advisory Board member

Dr. Stéphane MOUTEL holds a PhD in “Organic Chemistry” from the University of Orléans (France) and a PMP® certification with more than 20 years of experience in Biopharmaceutical companies. In 2001, Stéphane joined OM Pharma in Switzerland, where he first worked in the early phase drug development for small-molecule immunomodulators then he managed and coordinated all external CMC activities of the preclinical development of some vaccine adjuvants. Stéphane worked for Novimmune in 2017 as CMC Project Manager and led the CMC development of bi-specific antibodies.

Stéphane joined Swedish Orphan Biovitrum, who acquired Gamifant® and related assets in July 2019 from Novimmune, as Head of CMC Project Management and manages CMC projects at the late stage development in immunology (Gamifant® / emapalumab) and hematology (Efanesoctocog alfa/BIVV001 and Doptelet®) fields.

Board of Directors

David Sourdive

David Sourdive
Chairman

David Sourdive, Ph.D., is a co-founder and current Executive Vice President Strategic Initiatives of Cellectis and member of its Board of Directors. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. In addition to his role at Cellectis, Dr. Sourdive has also served on the board of directors of the Mediterranean Institute for Life Sciences.

David is graduated from École Polytechnique, earned his Ph.D. in molecular virology at Institut Pasteur and completed a research fellowship in the department of Microbiology and Immunology of Emory University.

Florian Denis

Florian Denis
Director

Florian Denis is an Investment Director at Elaia, which he joined in 2019 with a life sciences background, bringing almost 5 years of investment experience. Before joining Elaia, he operated at Auriga Partners where he invested and served on the Board of Directors of several French biotechnology companies such as Theranexus (ALTHX) and VitaDX. More recently, Florian worked in the Equity Research division of Gilbert Dupont (Société Générale) where he covered biotech / medtech / cleantech companies.

Florian holds a Master of Science (MSc) from the MTI master’s (Paris-Dauphine, ENS, Mines Paristech) and from Sup’Biotech Paris.

Jérémie Waicenberg

Jémérie Waicenberg
Director

Jérémie Waicenberg started his career as an Analyst in the life sciences team of Seventure Partners – a Venture Capital fund based in Paris. After managing the life sciences licensing activity at France Brevets – an alternative asset fund – he worked as a start-up executive for several companies and also managed out-licensing activities for a Tech Transfer Office based in Paris. He joined Mérieux Equity Partners mid-2019 and focuses his efforts on seed and early-stage investments within the firm.

Jérémie holds an engineering degree from Sup’Biotech with a major in Entrepreneurship.

Jérôme Majoie

Jérôme Majoie
Director

Jérôme Majoie is the Chairman and CEO of the Foundation Fournier-Majoie. Before joining the Fondation, he was the Managing Director of the Laboratories Fournier subsidiaries in the USA, UK, Sweden and Japan.

Jérôme is an ESDE graduate, and he holds an MBA in Management and International Marketing from the University of Hartford (Connecticut, USA).

Bervin Bouani

Bervin Bouani
Director

Currently Investment Director at Turenne Capital, Bervin Bouani is in charge of the Sham Innovation Santé fund. He serves on the Boards of several companies including HalioDx, Brainever, Orega Biotech, Pixee Medical… Prior to joining Turenne Capital in 2014, Bervin spent six years as an asset manager at SHAM, an insurer specialized in healthcare companies’ risks. There, he was involved in the development of the private equity business. He began his career as a junior financial engineer at CM-CIC.

Bervin holds a Master’s degree in Finance (Catholic University of Lille, and EDHEC Business School).

Jean-Guillaume Lafay, C.E.O.

Jean-Guillaume Lafay
Director

Mr. Jean-Guillaume Lafay holds a Master’s degree in Medicinal Organic Chemistry (University of Lyon, France). He has a strong entrepreneurship background and a great experience in management. He joined a France-based biotechnology company in 2010 as Sales & Marketing Director.

Stephane Legastelois

Stéphane Legastelois
Observer

Stéphane Legastelois has recently created 33 Californie, an Investment company that supports entrepreneurs in the life science sector. In parallel, Stéphane is also President of Simba Santé 3 (Angelor group), a seed capital player dedicated to disruptive health companies. Before switching to the investment side, Stéphane founded Indicia in 1998, a multidisciplinary CRO/CMO that he managed until the sale of the company in 2019.

Stéphane holds a Master Degree and a Ph.D. in in Biochemistry from the University of Lyon.

Emilie Richard

Emilie Richard
Observer

Emilie Richard joigned Crédit Agricole Création in 2015 where she works as an Investment Manager. Previously, she gained various experience working at Société Générale and Biojag.

Emilie holds a Master’s degree in Economic Science and Marketing from the University of Clermont Auvergne.